Baseline characteristics of patients with PSMA-PET–positive and –negative disease with high-risk BCR after radical RP

Enfortumab vedotin in combination with pembrolizumab is a potential new standard of care for 1L la/mUC

Lenvatinib and pembrolizumab show promising efficacy in first-line treatment of aRCC

Enzalutamide monotherapy prolongs MFS compared to leuprolide alone in men with high-risk biochemically recurrent PC

Combination of cabozantinib and atezolizumab shows moderate activity in treating metastatic adrenocortical carcinoma

Durvalumab plus bevacizumab, added to TACE, shows benefit for unresectable hepatocellular carcinoma

What is new for treatment of soft tissue and bone sarcomas?

Cancer personomics: Launching the missile - Localised endometrial carcinoma.

Novel therapies and combinations in ovarian cancer

What's new on ADCs in management of advanced NSCLC

Treatment of metastatic NSCLC without PD-L1 expression and without oncogene addiction

Personalised systemic treatment in advanced prostate cancer